 
        Dronabinol is not better than placebo for ALS cramps and fasciculations over 2 weeks
 
                                                    Dronabinol is not better than placebo for ALS cramps and fasciculations over 2 weeks
Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1135-40. doi: 10.1136/jnnp.2009.200642Synopsis
27 patients with amyotrophic lateral sclerosis (ALS) were randomized to receive either 5 mg dronabinol twice daily or placebo for 2 weeks in a randomized sequence. The purpose of this study was to determine if dronabinol decreases frequency and intensity of cramps and fasciculations compared to placebo, and if there are any improvements in sleep quality, functional ability, appetite and depression...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
 
                Learn about our AI Driven 
 High Impact Search Feature
     
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue 
                     
                 
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         LOGIN
                                    LOGIN
                                 
             
                        
Join the Conversation
Please Login or Join to leave comments.